ALP Bio
ALP Bio AG is a Swiss biotech startup developing a hybrid human tonsil organoid and AI platform that helps pharmaceutical and biotechnology companies assess and reduce anti-drug antibody (ADA) immunogenicity risk in therapeutic antibody programs earlier in drug development.
- Company typePrivate
- Founded2025
- HeadquartersSchlieren, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What ALP Bio does
ALP Bio AG is a Swiss biotechnology startup founded in 2025 and headquartered in Schlieren, Switzerland, with additional operations in San Diego, California. The company targets pharmaceutical and biotechnology developers of therapeutic antibodies, offering a hybrid platform for immunogenicity risk assessment that addresses anti-drug antibody (ADA) formation — a problem the company states affects up to 30% of biologic programs and typically only surfaces in clinical trials.
The platform is organized into three integrated layers: (1) an In silico ADA Screening module that uses protein language and geometric deep learning models to score antibody VH/VL sequences for epitope and overall ADA risk; (2) a proprietary Tonsil Organoid ADA Assay that validates candidates in a human-derived ex vivo system replicating B and T cell interactions; and (3) a Generative Biobetter Design module that uses AI to redesign flagged epitopes while preserving therapeutic function, cycling through iterative in vitro and ex vivo validation. The core differentiator is the proprietary tonsil organoid data, which the company positions as biological feedback that pure computational or animal models cannot replicate.
ALP Bio generates revenue through early-access collaboration programs with pharma and biotech partners, supplemented by platform licensing and biobetter asset co-development opportunities. The company sells through direct enterprise engagement rather than self-service channels, and pricing is not publicly disclosed. As of April 2026 the firm had just closed a USD 2.2 million pre-seed round led by Munich-based 42CAP, with participation from Ajira Ventures, Venture Kick, and strategic angels, and is in the early stages of commercial engagement.
ALP Bio firmographics
Firmographics- Name
- ALP Bio
- Legal name
- ALP Bio AG
- Website
- https://alp.bio
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ALP Bio AG is a Swiss biotech startup developing a hybrid human tonsil organoid and AI platform that helps pharmaceutical and biotechnology companies assess and reduce anti-drug antibody (ADA) immunogenicity risk in therapeutic antibody programs earlier in drug development.
- Ownership category
- akta.pro rank
ALP Bio industry classification
Industry- Product category
- Immunogenicity Intelligence Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where ALP Bio is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
ALP Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Platform partnership and early-access collaborations: ALP Bio generates revenue through early-access collaboration programs with pharmaceutical and biotechnology partners seeking immunogenicity characterization services. The company also offers platform licensing and biobetter asset co-development opportunities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
ALP Bio product offering
Product offeringCore offering
ALP Bio operates a hybrid immunogenicity intelligence platform that combines human tonsil-derived ex vivo immune organoid assays with protein AI models (protein language and geometric deep learning) to assess and reduce anti-drug antibody (ADA) risk in therapeutic antibodies. The integrated platform has three layers: (1) in silico ADA screening of VH/VL sequences, (2) tonsil organoid-based experimental validation, and (3) generative AI-driven biobetter sequence redesign through lab-in-the-loop iteration.
Product overview
ALP Bio is developing a unified hybrid platform for immunogenicity intelligence in biologics development. The platform integrates three core modules: (1) In silico ADA Screening for predictive sequence analysis, (2) Tonsil Organoid ADA Assay for experimental validation, and (3) Generative Biobetter Design for AI-powered sequence optimization. The platform is built on proprietary human tonsil organoid technology combined with protein AI models to help antibody developers predict and reduce anti-drug antibody risk earlier in the discovery process.
Differentiator
Problem solved
Functional benefit
Products and services
- In silico ADA Screening (Predict Layer) AI-powered screening module using protein language and geometric deep learning models to assess VH/VL antibody sequences for epitope and overall ADA risk, enabling large-scale antibody panel evaluation and identification of lowest-risk candidates early in development.
- Tonsil Organoid ADA Assay (Validate Layer) Proprietary human tonsil-derived ex vivo assay that captures B and T cell immune interactions to reveal candidate-specific immunogenic risk across patient populations. Delivered as a validation service within the platform.
- Generative Biobetter Design (Re-engineer Layer) AI-powered sequence redesign module that uses generative AI to redesign flagged epitopes to preserve therapeutic function while reducing immunogenic risk through iterative lab-in-the-loop cycles between design, in vitro testing, and ex vivo validation.
Quantifiable outcome
- ADA formation affects up to 30% of biologic programs
Companies that use ALP Bio
Customer profileSegments1 record
Ideal customer profiles1 record
ALP Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
ALP Bio partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights5 records
ALP Bio competitors and assessment
Company assessmentEmerging players
- Antiverse: Antiverse applies AI to antibody design and discovery, with overlap on computational antibody engineering but a narrower technology stack than ALP Bio's organoid-validated platform.
- Cradle: Cradle uses generative AI for protein design across multiple modalities; it is comparable as an AI protein design peer that overlaps with ALP Bio's biobetter design module but lacks ALP Bio's wet-lab validation layer.
- EvolutionaryScale: EvolutionaryScale develops frontier AI models for protein design and is comparable to ALP Bio on the protein AI infrastructure layer, though without the organoid validation component.
Broad incumbents
- Isomorphic Labs: Isomorphic Labs (Alphabet) is a well-capitalized AI drug discovery company pursuing protein design across therapeutic areas, representing a broad incumbent whose capabilities could eventually extend into immunogenicity prediction.
- AbCellera: AbCellera operates a leading antibody discovery platform partnering with pharma, and represents a broad incumbent whose partner ecosystem overlaps with ALP Bio's target buyer base.
Direct peers
- Absci: Absci is an AI-driven biologics discovery company with a generative AI platform for designing novel antibodies, directly comparable to ALP Bio's antibody design and developability mission.
- Adagene: Adagene is a clinical-stage immunology-focused company using computational and AI approaches to engineer antibodies with reduced immunogenicity, making it a directly comparable peer in the immunogenicity-intelligence niche.
- Generate Biomedicines: Generate Biomedicines applies generative AI to program novel protein therapeutics end-to-end, including antibody engineering, making it a direct comparability point for ALP Bio's generative biobetter design capabilities.
- Prellis Biologics: Prellis Biologics builds human immune system organoids (including lymph node-derived systems) for antibody discovery, providing the closest peer based on the use of ex vivo human immune organoids to inform antibody engineering.
- BigHat Biosciences: BigHat Biosciences uses an AI + wet-lab (lab-in-the-loop) platform to design and engineer better antibodies, closely mirroring ALP Bio's predict-validate-re-engineer architecture for therapeutic antibody optimization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
ALP Bio social profiles
Digital presenceALP Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ALP Bio leadership team
Management profileNumber of profiles
Profiles4 records
ALP Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ALP Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ALP Bio
What does ALP Bio do?
ALP Bio operates a hybrid immunogenicity intelligence platform that combines human tonsil-derived ex vivo immune organoid assays with protein AI models (protein language and geometric deep learning) to assess and reduce anti-drug antibody (ADA) risk in therapeutic antibodies. The integrated platform has three layers: (1) in silico ADA screening of VH/VL sequences, (2) tonsil organoid-based experimental validation, and (3) generative AI-driven biobetter sequence redesign through lab-in-the-loop iteration.
Is ALP Bio a public or private company?
ALP Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was ALP Bio founded?
ALP Bio was founded in 2025. It employs 1 to 10 people.
Where is ALP Bio based?
ALP Bio is headquartered in Schlieren, Switzerland, in the Europe region.
How does ALP Bio make money?
One revenue line is on record: platform partnership and early-access collaborations.
Who are ALP Bio's main competitors?
Emerging players on record are Antiverse, Cradle and EvolutionaryScale. Broad incumbents are Isomorphic Labs and AbCellera. Direct peers are Absci, Adagene, Generate Biomedicines, Prellis Biologics and BigHat Biosciences.
Does ALP Bio have an API?
No public API is recorded for ALP Bio.
What industry is ALP Bio in?
ALP Bio's product category is Immunogenicity Intelligence Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8071.